GlaxoSmithKline has won a $63.3 million contract from Health and Human Services to develop pre-pandemic and pandemic vaccines, supporting its research into adjuvants that boost the effectiveness of vaccines. The 5-year contract also gives the U.S. Government the option to fund an additional $44 million of future clinical development programs related to antigen-sparing pandemic vaccines. Iomai, meanwhile, announced it will receive a contract from HHS to fund the development of a dose-sparing patch for use with a pandemic influenza vaccine.
A limited global supply capacity of flu antigen makes it critical that we use innovative adjuvant system technology to produce a new generation of flu pandemic vaccines," said David Stout, president of pharmaceuticals at GlaxoSmithKline.
- here's the release on GSK's contract
- and here's the release on Iomai